{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:55:54Z","timestamp":1766048154138,"version":"3.37.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejca.2009.04.022","type":"journal-article","created":{"date-parts":[[2009,5,22]],"date-time":"2009-05-22T00:47:17Z","timestamp":1242953237000},"page":"1909-1915","source":"Crossref","is-referenced-by-count":52,"title":["Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy?"],"prefix":"10.1016","volume":"45","author":[{"given":"R.E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.04.022_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2407-2-37","article-title":"Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease","volume":"2","author":"Shibuya","year":"2002","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2009.04.022_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CBC.2005.n.045","article-title":"Reducing the global breast cancer burden: the importance of patterns of care research","volume":"6","author":"Albain","year":"2005","journal-title":"Clin Breast Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2009.04.022_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2009.04.022_bib4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1101\/gad.1449506","article-title":"Genetic regulation of bone mass and susceptibility to osteoporosis","volume":"20","author":"Ralston","year":"2006","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.ejca.2009.04.022_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cr.7290266","article-title":"Mechanisms of cancer metastasis to the bone","volume":"15","author":"Yin","year":"2005","journal-title":"Cell Res"},{"key":"10.1016\/j.ejca.2009.04.022_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","article-title":"Crosstalk between cancer cells and bone microenvironment in bone metastasis","volume":"328","author":"Yoneda","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejca.2009.04.022_bib7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ejca.2009.04.022_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.ejca.2009.04.022_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2009.04.022_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"Monkkonen","year":"2006","journal-title":"Brit J Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2009.04.022_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2009.04.022_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001813-200501000-00002","article-title":"Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion","volume":"16","author":"Woodward","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2009.04.022_bib13","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.04.022_bib14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2009.04.022_bib15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid. Induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2009.04.022_bib16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Neville-Webbe","year":"2005","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2009.04.022_bib17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.04.022_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","article-title":"Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment","volume":"28","author":"Mundy","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2009.04.022_bib19","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse, improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2009.04.022_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.04.022_bib21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"12","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2009.04.022_bib22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2009.04.022_bib23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2009.04.022_bib24","first-page":"109","article-title":"Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer","volume":"57","author":"van Holten-Verzantvoort","year":"1997","journal-title":"Medicina (B Aires)"},{"issue":"14S","key":"10.1016\/j.ejca.2009.04.022_bib25","article-title":"Adjuvant pamidronate (PMT) therapy for the prevention of bone metastases in breast cancer (BC) patients with four or more positive nodes","volume":"22","author":"Kokufu","year":"2004","journal-title":"ASCO (Ann Meeting Proc)"},{"key":"10.1016\/j.ejca.2009.04.022_bib26","doi-asserted-by":"crossref","unstructured":"Jung J, Hwang G, Lee Y, Park H, Yang Y. Pamidronate as adjuvant treatment for prevention of bone metastases in breast cancer. ASCO (Annual Meeting Proceedings) 2005 [Abs 888. 30].","DOI":"10.1200\/jco.2005.23.16_suppl.888"},{"issue":"4","key":"10.1016\/j.ejca.2009.04.022_bib27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2009.04.022_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2008-1046707","article-title":"Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study","volume":"133","author":"Rack","year":"2008","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ejca.2009.04.022_bib29","first-page":"68","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow","author":"Lin","year":"2007","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2009.04.022_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2009.04.022_bib31","first-page":"S57","article-title":"An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (Bca) receiving adjuvant letrozole (LET)","volume":"16","author":"Brufsky","year":"2007","journal-title":"The Breast"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2009.04.022_bib32","article-title":"The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST","volume":"69","author":"Eidtmann","year":"2008","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2009.04.022_bib33","article-title":"Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy\u2013first safety data from the AZURE trial (BIG01\/04)","volume":"100","author":"Coleman","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2009.04.022_bib34","first-page":"S75","article-title":"Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: initial dental safety findings from the AZURE study","volume":"34","author":"Burkinshaw","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2009.04.022_bib35","article-title":"The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response \u2013 exploratory evidence for direct anti-tumour activity in breast cancer","volume":"69","author":"Winter","year":"2008","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:52:22Z","timestamp":1739119942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909003062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0959804909003062"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.04.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}